Immediate local and systemic hypersensitivity due to etanercept and adalimumab

J Allergy Clin Immunol Pract. 2019 Feb;7(2):726-727. doi: 10.1016/j.jaip.2018.06.020. Epub 2018 Jul 10.

Authors

Katharina Hansel¹, Leonardo Bianchi¹, Marta Tramontana¹, Anna Balato², Emanuele Scala³, Jacopo Brozzi¹, Luca Stingeni⁴

Affiliations

¹ Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy.
² Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
³ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁴ Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy. Electronic address: [email protected].

PMID: 30006049
DOI: 10.1016/j.jaip.2018.06.020

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / adverse effects*
Adalimumab / therapeutic use
Angioedema
Antirheumatic Agents / adverse effects*
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*
Drug Hypersensitivity / diagnosis*
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Etanercept / adverse effects*
Etanercept / therapeutic use
Female
Humans
Hypersensitivity, Immediate / diagnosis*
Immunoglobulin E / metabolism
Middle Aged
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Urticaria

Substances

Antirheumatic Agents
Tumor Necrosis Factor-alpha
Immunoglobulin E
Adalimumab
Etanercept